![]() |
市場調查報告書
商品編碼
1382515
全球語音義肢設備市場 - 2023-2030Global Voice Prosthesis Devices Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
稱為語音假體裝置的醫療設備可幫助接受喉切除手術的人恢復言語。喉切除術是一種切除喉部(喉部)的外科手術。這通常是為了應對癌症或其他與喉部相關的醫療問題。喉部切除的患者失去了天然聲帶,導致他們說話變得困難。發聲裝置對於提供發聲替代品至關重要。
隨著時間的推移,科技的發展增強了發聲假體裝置的功能和設計,改善了喉切除術患者的治療效果。在語言病理學家 (SLP) 的幫助下,語言治療對於學習如何有效地使用發聲假體是必要的。為了提高使用設備的言語和溝通能力,患者參與 SLP。用於發聲義肢的設備需要日常維護,包括因磨損而清潔和更換。
發展適當的預防和診斷方法,特別是在高風險族群中,對於喉癌這個重要腫瘤實體的預後至關重要。言語、吞嚥、呼吸、社會關係和情緒健康都會受到全喉切除術的顯著影響,這也會對生活品質產生不利影響。食道言語(ES)和氣管食道言語(TES)是全喉切除患者使用的兩種主要復健方法。 TES 涉及透過手術植入發聲假體,使來自肺部的空氣透過假體導入食道來發聲,而 TES 則相反,ES 使用咽食道段來發聲。
使用自動語音閥(ASV)實現常規的免持語音是喉切除術後言語治療的最終目標。 ASV 在氣管食道說話時會自動關閉,無需使用手指或手來堵塞氣管造口。由於患者在使用 ASV 時無法用手指指向造口,因此可以解放雙手,實現快速的口頭反應,並減輕對患者損傷的關注。
Inhealth Technologies 提供放置在 Blom-Singer 雙瓣膜留置發聲假體的兩個瓣膜中的氧化銀作為材料防腐劑。即使主閥發生故障,輔助說話閥也能發揮作用,有助於防止液體洩漏。標準或大型氣管/食道法蘭可用於 Blom-Singer 雙瓣發聲假體。包括插入/清潔設備和非無菌發聲假體,用於二次或替代 TEP 治療。
一大障礙是病患和醫療專業人員對發聲義肢設備的無知。在某些地區,獲得尖端技術和專家護理的機會也受到限制。特別是對於沒有足夠保險覆蓋或醫療資源稀缺地區的患者來說,與發聲假體裝置和相關醫療程序相關的高成本可能是一個巨大的障礙。需要專業的言語康復,這對某些患者來說可能既耗時又困難,才能學會有效地使用語音義肢設備。由於其複雜性,患者可能不會選擇此選項。
Medical devices called voice prosthesis devices assist people who have had laryngectomy surgeries in regaining their speech. A laryngectomy is a surgical surgery in which the larynx (voice box) is removed. This is frequently done in response to cancer or other larynx-related medical issues. Patients who have their larynx removed lose their natural vocal cords, making it hard for them to speak. Devices for voice prostheses are crucial in offering a substitute for vocalization.
Over time, technological developments have enhanced the functionality and design of vocal prosthesis devices, improving the outcomes for laryngectomy patients. With the aid of a speech-language pathologist (SLP), speech therapy is necessary to learn how to utilize a vocal prosthesis efficiently. To improve their speech and communication abilities using their device, patients engage with an SLP. Devices used for voice prostheses need routine care, including cleaning and replacement due to wear and tear.
The development of adequate preventative and diagnostic methods, particularly in high-risk populations, is crucial for the prognosis of laryngeal cancer, an important oncological entity. Speech, swallowing, breathing, social relations, and emotional health are all significantly impacted by total laryngectomy, which also has an adverse effect on quality of life. Esophageal speech (ES) and tracheoesophageal speech (TES) are the two primary rehabilitation methods used with complete laryngectomy patients. In contrast to TES, which involves surgically implanting a vocal prosthesis that permits air from the lungs to be directed via the prosthesis into the esophagus to make sound, ES uses the pharyngoesophageal segment to produce sound.
Achieving regular hands-free speech with an automated speaking valve (ASV) is the ultimate goal of speech therapy after a laryngectomy. The ASV automatically closes during tracheoesophageal speaking, negating the need to use a finger or hand to occlude the tracheostoma. Because the patient cannot point with his finger at his stoma when using an ASV, it frees up his hands, enables quick verbal response, and lessens the focus on his impairment.
Inhealth Technologies provides silver oxide placed in two valves of the Blom-Singer Dual Valve Indwelling Voice Prosthesis as a material preservative. The secondary speaking valve is designed to function even if the primary valve fails, helping to stop fluid leaking. Standard or large tracheal/esophageal flanges are available for the Blom-Singer Dual Valve Voice Prosthesis. Includes insertion/cleaning equipment and a non-sterile vocal prosthesis for use in secondary or replacement TEP treatments.
One big barrier is patients' and healthcare professionals' ignorance about vocal prosthetic equipment. Accessibility to cutting-edge technology and specialist care also be restricted in some areas. Particularly for patients without adequate insurance coverage or in areas with scarce healthcare resources, high costs connected with vocal prosthesis devices and related medical procedures can be a substantial barrier. It takes specialist speech rehabilitation, which can be time-consuming and difficult for some patients, to learn to utilize voice prosthesis devices efficiently. This option may not be chosen by patients because of its intricacy.
The global voice prosthesis devices market is segmented based on product type, end-user, and region.
When a person has had their larynx (voice box) removed during a laryngectomy treatment, they will utilize indwelling voice prosthesis devices, also known as indwelling tracheoesophageal voice prostheses (TVP). In order to improve speech and communication for laryngectomy patients, these devices are surgically placed.
Patients with laryngeal malignancies who have had laryngectomy may benefit from voice prosthesis (VPs), which are indwelling silicone valves used for speech therapy. A significant issue is the microbial biofilm buildup on VPs, which need frequent replacement and raises the risk of pneumonia and chest infections.
Microbial development is encouraged in the esophagus, where they are exposed to food, saliva, liquids, humidity, and temperatures around 37 °C. The inclusion of silver oxide (Blom Singer Advantage) and Teflon-like fluoroplastic (Provox ActiValve) into the VPs material to inhibit microbial colonization are just two strategies that have been suggested to lengthen the lifespan of the VPs.
North America has been a dominant force in the global voice prosthesis devices market. The most recent projections from the American Cancer Society for the number of new cases of laryngeal cancer in the United States in 2023 are 12,380 (9,900 in men and 2,480 in women). 750 women and 3,820 men will pass away from laryngeal cancer. About 35% of laryngeal malignancies develop above the vocal cords in the supraglottic region, while 60% begin in the glottis (the region containing the vocal cords).
A relatively tiny percentage of those who are diagnosed with laryngeal cancer are under the age of 55. Laryngeal cancer diagnoses typically occur in adults 66 and older.
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global voice prosthesis devices market. The pandemic affected the manufacturing and distribution of medical goods, especially voice prosthesis, by upsetting worldwide supply networks. This might have caused brief shortages and delays in the availability of devices.
Numerous healthcare resources were diverted to deal with the pandemic's immediate crisis, which can have an impact on elective procedures and rehabilitation plans, particularly those using vocal prosthetic devices. During the pandemic, patients had reluctant to have elective surgery, which might have decreased the number of laryngectomy procedures and consequently the demand for voice prosthetic devices.
major global players in the market include: F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Regeneron Pharmaceuticals, ICU Medical Inc., HEIMOMED Heinze, Atos Medical, and Servona Acclarent Inc.
The global voice prosthesis devices market report would provide approximately 46 tables, 53 figures, and 186 Pages.
LIST NOT EXHAUSTIVE